Mutation topography and risk stratification for de novo acute myeloid leukaemia with normal cytogenetics and no nucleophosmin 1 (NPM1) mutation or Fms‐like tyrosine kinase 3 internal tandem duplication (FLT3‐ITD)

Summary About 25% of patients with newly diagnosed acute myeloid leukaemia (AML) have normal cytogenetics and no nucleophosmin 1 (NPM1) mutation or Fms‐like tyrosine kinase 3 internal tandem duplication (FLT3‐ITD). The prognosis and best therapy for these patients is controversial. We evaluated 158...

Ausführliche Beschreibung